AUS
NZ
UK
CA
USA
IND
Highlights
- PromarkerD launched in Australia for early diabetic kidney disease detection
- Study shows PromarkerD outperforms standard tests in predicting kidney function decline
- Engagement with stakeholders to expand accessibility and adoption
Proteomics International Laboratories (ASX:PIQ) has officially introduced its groundbreaking PromarkerD predictive test in Australia. This clinically validated blood test helps identify the risk of developing diabetic kidney disease (DKD) in individuals with type 2 diabetes, offering an early diagnosis window of up to four years before symptoms manifest.
With diabetes being the leading cause of chronic kidney disease worldwide, the need for early detection is more critical than ever. In Australia alone, over 1.3 million people are living with diabetes, highlighting the significance of advanced diagnostic tools like PromarkerD.
Advancing Early Diagnosis and Patient Care
Early detection plays a crucial role in managing chronic conditions. The ability to identify individuals at high risk allows healthcare providers to implement timely interventions, potentially reducing complications such as renal failure, dialysis, or the need for a transplant.
Dr. Richard Lipscombe, managing director of (PIQ), emphasized the importance of this milestone, aligning it with World Kidney Day. He noted that DKD is a significant public health challenge, and PromarkerD offers an innovative, accurate, and accessible solution for proactive disease management.
By improving early identification, the test aims to alleviate both personal and financial burdens associated with diabetic kidney disease, providing an opportunity for better patient outcomes.
Strategic Expansion and Industry Collaboration
As part of its broader strategy, (PIQ) is actively engaging with key stakeholders across primary care networks, diabetes clinics, and professional medical organizations. Collaborations with health insurers, government agencies, and patient advocacy groups are also being explored to integrate the test into standard healthcare practices.
Initially, PromarkerD will be available through a direct-to-consumer approach, serving as a stepping stone toward partnerships with major diagnostics industry players.
Breakthrough Study Confirms Effectiveness
Recent research further supports the impact of PromarkerD in predicting future kidney function decline. A landmark study, published in the peer-reviewed journal Diagnostics, highlighted that PromarkerD significantly outperforms traditional tests in assessing renal function deterioration in type 2 diabetes patients.
This validation strengthens its credibility within the medical community, positioning it as a powerful tool for healthcare professionals. The study reinforces the need for more effective predictive solutions, paving the way for broader adoption.
With the launch of PromarkerD, (PIQ) is advancing early detection efforts in diabetic kidney disease, offering new hope for patients and improving long-term healthcare strategies.
